Back to Journals » Neurobehavioral HIV Medicine » Volume 2
Variable cognitive benefits in HAART-treated patients: are aging and low cholesterol linked?
María Jose Míguez-Burbano1, John E Lewis2, Ximena Burbano3, Rhonda Rosenberg1, Joel Fishman4, Deshratn Asthana2, Karl Goodkin5, Robert M Malow1
1Department of Health Promotion and Disease Prevention, Robert Stempel College of Public Health and Social Work and College of Medicine, Florida International University, Miami, FL, USA; 2Departments of Psychiatry and Behavioral Sciences, 3Epidemiology and Public Health, and 4Radiology, University of Miami Miller School of Medicine, Miami, FL, USA; 5Department of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center and Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
Objective: Since a sizeable portion of the brain is composed of cholesterol, which serves various vital functions, we investigated interrelationships among hypocholesterolemia (HypoCHL < 150 mg/dL) and neurocognitive impairment for people living with HIV (PLWH).
Methods: Fasting blood samples were obtained in 125 PLWH younger than 45 years of age (Group 1) and 40 PLWH older than 46 years old (Group 2) at baseline and after 24 weeks on highly active antiretroviral therapy (HAART). Participants with HypoCHL were compared with non-HypoCHL on learning/memory (California Verbal Learning Test = CVLT) and global neurocognitive status (HIV Dementia Scale = HDS).
Results: HypoCHL was prevalent in Group 1 (35%) and Group 2 (30%) and associated with lower CVLT (P = 0.03) and HDS (P = 0.02) scores. After HAART in Group 1, non-HypoCHL subjects improved in every neurocognitive parameter, but progress was limited and non-significant in the HypoCHL subjects. Despite better adherence and lower viral loads (P = 0.05) exhibited by Group 2, the HypoCHL participants showed declines in HDS scores (-2.5) and total CVLT (-0.86 words). After adjusting for relevant variables, HypoCHL subjects from Group 1 showed a three-fold increased risk for scoring in the dementia range (P < 0.01), and the risk was even higher for HypoCHL participants in Group 2 (OR = 5.0, 95% CI: 1.25–21.3, P = 0.008).
Conclusions: The association of HypoCHL with limited HAART neurocognitive recovery and even a continuous decline indicates the importance of restoring lipid balance.
Keywords: lipids, metabolism, cognition, HIV-associated neurocognitive disorders, HAART, HIV/AIDS
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Published Date: 19 November 2015
Neuropsychological profile in a specific cohort of HIV patients infected postnatally: a cross-sectional study
Riva S, Cutica I, Pravettoni G
Published Date: 9 October 2015
Carr ME, Tortella BJ
Published Date: 3 September 2015
Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
Cai Y, An SSA, Kim SY
Published Date: 14 July 2015
Janbain M, Leissinger CA, Kruse-Jarres R
Published Date: 8 May 2015
Published Date: 12 December 2014
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A
Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S
Published Date: 16 May 2014
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
Lentz SR, Tandra A, Gut RZ, Cooper DL
Published Date: 13 January 2014
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
Published Date: 6 August 2010
Timothy J Nelson, Almudena Martinez-Fernandez, Satsuki Yamada, et al
Published Date: 22 December 2009